A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists
(2016) In European Journal of Neurology 23(8). p.1255-1261- Abstract
Background and purpose: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal)... (More)
Background and purpose: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal) across a broad range of disease stages and age groups was performed. Results: Four hundred and twenty-five cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P <0.05) compared with any other assessed DAs except for prolonged release PPX (PPX-PR). The rate of ICDs for PPX-PR (6.6%) was significantly lower than for immediate release PPX (PPX-IR) (19.0%; P <0.05). Discontinuation rates of DA therapy due to ICDs were low. Conclusion: Our data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.
(Less)
- author
- organization
- publishing date
- 2016-08-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Dopamine agonists, Dopamine dysregulation syndrome, Impulse control behaviours/disorders, Parkinson's disease
- in
- European Journal of Neurology
- volume
- 23
- issue
- 8
- pages
- 1255 - 1261
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:27170229
- wos:000380102300010
- scopus:84978498958
- ISSN
- 1351-5101
- DOI
- 10.1111/ene.13034
- language
- English
- LU publication?
- yes
- id
- 40e099e3-4c96-4422-a8c4-3a6bff21bcfa
- date added to LUP
- 2016-06-21 15:13:24
- date last changed
- 2022-12-06 04:59:55
@article{40e099e3-4c96-4422-a8c4-3a6bff21bcfa, abstract = {{<p>Background and purpose: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal) across a broad range of disease stages and age groups was performed. Results: Four hundred and twenty-five cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P <0.05) compared with any other assessed DAs except for prolonged release PPX (PPX-PR). The rate of ICDs for PPX-PR (6.6%) was significantly lower than for immediate release PPX (PPX-IR) (19.0%; P <0.05). Discontinuation rates of DA therapy due to ICDs were low. Conclusion: Our data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.</p>}}, author = {{Rizos, A. and Sauerbier, A. and Antonini, A. and Weintraub, D. and Martinez-Martin, P. and Kessel, B. and Henriksen, T. and Falup-Pecurariu, C. and Silverdale, M. and Durner, G. and Røkenes Karlsen, K. and Grilo, M. and Odin, P. and Chaudhuri, K. Ray}}, issn = {{1351-5101}}, keywords = {{Dopamine agonists; Dopamine dysregulation syndrome; Impulse control behaviours/disorders; Parkinson's disease}}, language = {{eng}}, month = {{08}}, number = {{8}}, pages = {{1255--1261}}, publisher = {{Wiley-Blackwell}}, series = {{European Journal of Neurology}}, title = {{A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists}}, url = {{http://dx.doi.org/10.1111/ene.13034}}, doi = {{10.1111/ene.13034}}, volume = {{23}}, year = {{2016}}, }